Bausch Health Cos Inc. $BHC Shares Sold by Compass Rose Asset Management LP

Compass Rose Asset Management LP reduced its position in Bausch Health Cos Inc. (NYSE:BHC) by 50.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 250,000 shares of the company’s stock after selling 250,000 shares during the period. Bausch Health Cos makes up about 0.3% of Compass Rose Asset Management LP’s holdings, making the stock its 14th biggest holding. Compass Rose Asset Management LP’s holdings in Bausch Health Cos were worth $1,612,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of BHC. Goldentree Asset Management LP increased its position in shares of Bausch Health Cos by 13.2% during the second quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock worth $227,848,000 after acquiring an additional 4,004,889 shares during the last quarter. Paulson & CO. Inc. boosted its holdings in Bausch Health Cos by 24.0% in the second quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock valued at $218,393,000 after purchasing an additional 6,352,667 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Bausch Health Cos by 4.0% in the third quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock valued at $78,808,000 after purchasing an additional 470,968 shares during the last quarter. Maple Rock Capital Partners Inc. grew its stake in Bausch Health Cos by 14.9% during the 2nd quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after purchasing an additional 1,010,987 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Bausch Health Cos by 114.4% during the 2nd quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock valued at $40,979,000 after purchasing an additional 3,282,684 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Trading Down 1.7%

Shares of NYSE BHC opened at $4.97 on Friday. The stock’s 50 day moving average price is $6.20 and its two-hundred day moving average price is $6.53. Bausch Health Cos Inc. has a 52-week low of $4.25 and a 52-week high of $8.69. The stock has a market capitalization of $1.85 billion, a P/E ratio of 11.82 and a beta of 0.37. The company has a quick ratio of 1.08, a current ratio of 1.47 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last issued its earnings results on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The firm had revenue of $2.78 billion during the quarter, compared to analyst estimates of $2.71 billion. On average, analysts anticipate that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Trending Headlines about Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks bumped some near‑term/near‑term‑adjacent forecasts — including FY‑2026 (to $3.92 EPS), Q4‑2026 (to $1.10), Q1‑2027 (to $0.82) and Q3‑2027 (to $1.12) — suggesting parts of the company’s near‑term earnings outlook improved. Zacks revisions (summary)
• Neutral Sentiment: Zacks published an FY‑2028 estimate ($3.36 EPS) which provides a longer‑horizon view but is farther out and less likely to move the stock materially in the short term. FY‑2028 estimate
• Negative Sentiment: Zacks trimmed a number of core near‑term forecasts: Q2‑2027 EPS was cut notably (from $0.96 to $0.89) and Zacks reduced its FY‑2027 outlook (to $3.79 from $3.85), along with cuts to several quarterly estimates — a driver of downward earnings expectations and selling pressure. Zacks cuts (summary)
• Negative Sentiment: The Portnoy Law Firm has opened an investigation into Bausch + Lomb Corporation (BLCO) for possible securities fraud; while that probe targets BLCO, market participants may view it as a reputational/legal overhang for companies carrying the Bausch name or related assets, increasing risk sentiment. Bausch + Lomb investigated (GlobeNewswire)

Analyst Upgrades and Downgrades

Several research firms have issued reports on BHC. Truist Financial lifted their price objective on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Raymond James Financial restated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Barclays cut their price target on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Finally, Weiss Ratings downgraded shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $8.33.

Bausch Health Cos Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.